Latest Zealand Pharma News & Updates

See the latest news and media coverage for Zealand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Zealand Pharma

Biotechnology company developing peptide and small-molecule medicines

zealandpharma.com

Headquarters: Søborg (Copenhagen), Denmark
Founded year: 1998
Company type: Public company
Number of employees: 200–700
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Zealand Pharma

In short: Zealand Pharma advanced its obesity drug pipeline into Phase 3 trials and initiated a DKK 1.3 billion share buy-back program.

Company announcements

August 24 Zealand Pharma

Zealand Pharma corrects reported share buy-back transaction dates

The amendment updates the weekly transaction table for late August, reflecting daily purchases executed on Nasdaq Copenhagen under its DKK 1.3 billion program.

August 13 Zealand Pharma

Zealand Pharma sells rusfertide royalty rights for one hundred million dollars

The transaction provides immediate capital for strategic priorities while retaining partial future sales incentives beyond a fifteen billion threshold.

August 10 Zealand Pharma

Zealand Pharma reports weekly share repurchase transactions for week 32

The biotechnology firm acquired 131,000 shares at an average price of roughly DKK 321, bringing its total treasury holdings to over 3.3 million shares.

July 20 Zealand Pharma

Zealand Pharma reports share buy-back transactions for week 30, 2026

The company repurchased 198,000 shares at an average price of approximately DKK 295 per share.

Media coverage

September 8 Euroinvestor

Lowers recommendation of Zealand Pharma: How much the stock can rise from here

The large bank has indeed lowered its recommendation of the Danish biotech stock from previously overweight to now equal weight. Thus, the large bank recommends that one hold back and neither...

September 1 Yahoo Finance

Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights...

September 1 Økonomisk Ugebrev

Zealand Pharma: Important Petrelintide data on the way

The Zealand Pharma stock has not made much of a fuss in recent months. This may change when ZUPREME-2 top-line...

August 13 BioSpace

Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M

The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies...

Never miss news about Zealand Pharma

Track Zealand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Zealand Pharma competitors & trending companies

Browse news for competitors to Zealand Pharma and other trending companies.